Outlook for 2009

Updated on 26 October 2009

Net sales will increase slightly compared with 2008. Sales of pharmaceuticals through Orion’s own sales network will continue to increase in Finland and other European countries. Global in-market sales of Comtess/Comtan and Stalevo drugs will show further growth, but at a slower rate than before. Deliveries of Parkinson’s drugs to Novartis are expected to increase.

Marketing expenditure will increase due to the launching of sales and marketing activities in several countries for Simdax, which was repurchased from Abbott, as well as the launching of other products. Research expenditure will be slightly higher than in 2008. The costs of ongoing patent litigation in the United States are estimated to be higher than in 2008.

Operating profit excluding non-recurring items is forecast to be slightly higher than in 2008. In addition, a non-recurring payment of EUR 4 million to be received from Pfizer later this year would increase the operating profit. A prerequisite for the payment is that the European Commission approves the agreement between Orion and Pfizer concerning reversion of animal sedative marketing rights in Europe to Orion.

R&D expenses will be about EUR 95 million. In addition, about EUR 10 million will be used to support products already on the market. The latter item is now included in costs of goods sold in the Statement of Comprehensive Income, while previously both items were included in R&D expenses.

The Group’s capital expenditure will be about EUR 65 million, including the repurchase of Simdax but excluding other new substantial company or product acquisitions.

Published on 7 August 2009

Net sales will increase slightly compared with 2008. The sales of pharmaceuticals through Orion’s own sales network will increase both in Finland and other European countries. Global in-market sales of the Comtess/Comtan and Stalevo drugs will show further growth, but at a slower rate than before. Deliveries of Parkinson’s drugs to Novartis are expected to increase.

Marketing expenditure will increase due to the launching of sales and marketing activities for Simdax, which was repurchased from Abbott, in several countries, as well as the launching of other products. Research expenditure will remain at the previous year’s level. The costs of the patent infringement lawsuits underway in the United States are estimated to be higher than in 2008.

Operating profit is estimated to increase slightly from 2008. The global economic recession is not expected to have a material effect on the results, but it will complicate the assessment of profitability.

R&D expenses will be about EUR 90 million. Additionally, about EUR 10 million will be used to promote products already on the market. The latter item is now included in Costs of goods sold in the Income Statement, while previously both items were included in Research expenditure.

The Group’s capital expenditure will be about EUR 65 million, including the repurchase of Simdax but excluding other substantial company or product acquisitions.

Published on 27 April 2009

Net sales will increase slightly from 2008. Sales of pharmaceuticals through Orion’s own sales network will continue to increase both in Finland and other European countries. Global in-market sales of the Comtess/Comtan and Stalevo drugs will show further growth, but at a slower rate than before. Deliveries of Parkinson’s drugs to Novartis are expected to increase slightly.

Marketing expenditure will increase moderately, mainly owing to product launches. Research expenditure will remain at the level of 2008. The on-going patent litigations in the United States will continue. Their costs are estimated to be slightly higher than in 2008.

Operating profit is estimated to increase slightly from 2008. The economic crisis is not estimated to have a material effect on the result, but the crisis increases uncertainty relating to profitability estimates.

R&D expenses will be about EUR 90 million. Additionally, about EUR 10 million will be used in maintenance of product portfolios that are already on the market. The latter item is now included in costs of goods sold in the income statement, while previously both items were included in R&D expenses.

Capital expenditure will be about EUR 45 million, not including substantial company or product acquisitions.

Published on 6 February 2009

Net sales will grow slightly from 2008. Sales of pharmaceuticals through Orion’s own sales network will continue to increase both in Finland and other European countries. Total in-market sales of Orion’s Parkinson’s drugs will show further growth, but at a slower rate than before. Deliveries of Parkinson’s drugs to Novartis are expected to increase slightly.

Marketing expenditure will increase moderately, mainly owing to product launches. Research expenditure will remain at the level of 2008. Internal, fixed R&D expenses will decrease as a result of the restructuring, but ongoing clinical studies and studies that are about to start will increase external costs. The ongoing patent litigations in the United States will continue. Their costs are estimated to be slightly higher than in 2008.

Operating profit is estimated to increase slightly from 2008. The economic crisis is not expected to have a material effect on the result, but the crisis increases uncertainty relating to profitability estimates.

R&D expenses will be about EUR 100 million.

Capital expenditure will be about EUR 45 million, not including substantial company or product acquisitions.